Avirmax生物制药公司自豪地在2026年科罗拉多州丹佛市的ARVO年会上展示成果-动脉网

Avirmax Biopharma Inc. Proudly Presents at the 2026 ARVO Annual Meeting in Denver, Colorado

CISION 等信源发布 2026-04-27 23:30



可切换为仅中文







HAYWARD, Calif.

加利福尼亚州海沃德

，

April 27, 2026

2026年4月27日

/PRNewswire/ -- Avirmax Inc. will deliver two scientific presentations at the 2026 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Denver, Colorado May 3 - 7, 2026. ARVO is the largest international society dedicated to ophthalmology and related visual sciences.

/PRNewswire/ -- Avirmax Inc. 将于2026年5月3日至7日在科罗拉多州丹佛举行的2026年视觉与眼科研究协会（ARVO）年会上发表两场科学报告。ARVO是致力于眼科及相关视觉科学的最大国际学会。

Title:

标题：

Analytical Integration of ddPCR and Protein Quantification Enhances Accuracy of AAV-Specific Vector Genome Determination

分析整合ddPCR和蛋白质定量提高了AAV特异性载体基因组测定的准确性

Presenter: Sameera Peraramelli, Ph.D.

主持人：萨米拉·佩拉拉梅利，博士

Session Title: Gene Editing and Gene Therapy II

会议标题：基因编辑与基因治疗 II

Session Date/Time: May 5, 2026, from 8:30 AM to 10:15 AM MDT

会议日期/时间：2026年5月5日，上午8:30至上午10:15（MDT）

Dr. Shengjiang Liu, Ph.D. Chief Executive and Scientific Officer will present '

刘盛江博士，首席执行官兼科学官将发表演讲

From Bench to Clinic: CMC and Preclinical Development of ABI-110 Gene Therapy for Ocular Neovascularized Disorders

从实验室到临床：ABI-110基因治疗视网膜新生血管疾病的CMC和临床前开发

', Poster-Board Number: 3655 – 0748, Session Number: 371, Session Title: AMD: Translational studies, Session Date/Times: May 5, 2026, from 3:30 PM to 5:15 PM.

`, 海报板编号：3655 - 0748，会议编号：371，会议标题：AMD：转化研究，会议日期/时间：2026年5月5日，下午3点30分至5点15分。`

These presentations will highlight the company's continued commitment to advancing ocular genetic medicine programs, including the development of its proprietary macular targeting capsid AAV.N54, vector manufacturing, testing & quality control, while also highlighting the importance of precise vector genome titer determination to enable accurate dose delivery in clinical trials, alongside the application of robust nonclinical models for treating wet AMD, including PCV..

这些报告将重点介绍公司持续致力于推进眼部基因药物项目，包括其专有的黄斑靶向衣壳AAV.N54的开发、载体生产、测试与质量控制，同时强调精确的载体基因组滴度测定在临床试验中实现准确剂量递送的重要性，以及应用稳健的非临床模型治疗湿性AMD（包括PCV）的应用。

Furthermore, Avirmax Biopharma will exhibit at Booth #5028 to showcase its latest advancements and comprehensive data packages.

此外，Avirmax Biopharma 将在5028号展位展示其最新的进展和全面的数据包。

About Avirmax Inc.

关于Avirmax公司

Avirmax Biopharma Inc. is a San Francisco-based company that specializes in developing rAAV-mediated therapeutics for ocular diseases using its AAV engineering technologies and Sf9-based AAV manufacturing platform. Since its inception, Avirmax Biopharma has been dedicated to developing safe, effective, and widely available AAV gene therapy products to meet the unmet needs of patients.

Avirmax Biopharma Inc. 是一家位于旧金山的公司，专注于利用其AAV工程技术和基于Sf9的AAV生产平台，开发用于眼部疾病的rAAV介导治疗药物。自成立以来，Avirmax Biopharma 一直致力于开发安全、有效且广泛可用的AAV基因治疗产品，以满足患者的未竟需求。

Please visit .

请访问。

avirmax.com

for more information.

更多信息，请参阅。

Contact

联系

June Song, Director of Operations

宋俊，运营总监

[email protected]

电子邮件地址